- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT01820598
Phase II Study of Neuromuscular Electrical Multisite System on Cardiovascular Effects in Severe Obese Patients (StimobII)
Acute and Medium-term Effects of Neuromuscular Electrical Multisite System (Kneehab®) on Cardiovascular Parameters and Induced Muscle Fatigue in Morbidly Obese Patients: Comparison With the Unidirectional Standard Device
The study was designed to test the following hypotheses:
In patients with severe obesity, a multisite electrostimulation session (m-NMES) will induce higher changes in metabolic, inflammatory and cardiovascular parameters and higher increase in muscle strength during stimulated contractions than conventional unidirectional electrostimulation session (c-NMES).
In patients with severe obesity, a six-weeks m-NMES training program will enhance cardiovascular, metabolic and inflammatory parameters.
Studienübersicht
Status
Intervention / Behandlung
Detaillierte Beschreibung
Background: Physical activity is known to reduce cardiovascular risk as far as even minor change in lifestyle could occur. In obesity, physical activity programs remain challenging due to multifactorial causes related to body mass such as shortness of breath, traumatological pain or psychosocial causes. Although neuromuscular electrical stimulation training is presently ignored in the management of obesity, this technique may be appropriate and useful for muscle deconditioning in these patients. Furthermore, direct effects of electrostimulation training program on vascular function have been previously reported in spinal cord injury and chronic heart disease, suggesting that improvement in cardiovascular function may be expected. While a promising new technique of multisite electrical stimulation (the Kneehab® system) has been recently commercialized, few study have investigated the acute effects of electrostimulation on vascular function and not any study report the effects of electrical stimulation in obese patients.
MAIN OUTCOME OF THE ACUTE PHASE STUDY (1st part):To study the effect of multisite electrical stimulation session (m-NMES) on arterial stiffness as compared to conventional unidirectional electrical stimulation session (c-NMES) in patients with severe obesity. Secondary outcomes of the observational study: 1/ To study the effect of m-NMES on endothelial function, blood pressure, systemic inflammation and metabolic status (fasting glucose and insulin) as well as electrically-induced muscle fatigue as compared with c-NMES in patients with morbid obesity. 2/ To study the profile of responders to electrical stimulation according to body composition, 6-minute walking distance, spontaneous physical activity or susceptibility to tolerate electrical stimulation. Response to electrical stimulation will be assessed by an improvement in arterial stiffness after stimulation, if so.
MAIN OUTCOME OF THE INTERVENTIONAL STUDY (2nd part):To study the effect of a multisite electrical stimulation training program (m-NMES) (6 weeks, 30 sessions) on arterial stiffness in patients with severe obesity. Secondary outcomes of the interventional study: To study the effect of m-NMES on endothelial function, blood pressure, systemic inflammation and metabolic status (fasting glucose and insulin) as well as muscle strength, body composition, functional capacity (6-minute walking distance) and spontaneous physical activity, after 15 sessions (3 weeks) and after 30 sessions (6 weeks) of training program. Evaluation of the dose-response to m-NMES training in terms of arterial stiffness and functional capacity.
Expected outcomes: Acute change in arterial stiffness and/or endothelial function is expected after one m-NMES session and/or after c-NMES session. M-NMES session is expected to induce higher changes than c-NMES stimulation session on cardiovascular and muscle parameters. Chronic changes in arterial stiffness and/or endothelial function is expected after 6 weeks of m-NMES training.
Studientyp
Einschreibung (Voraussichtlich)
Phase
- Unzutreffend
Kontakte und Standorte
Studienkontakt
- Name: Jean-Louis Pepin, MD, PhD
- Telefonnummer: 476765516
- E-Mail: JPepin@chu-grenoble.fr
Studieren Sie die Kontaktsicherung
- Name: Isabelle Vivodtzev, PhD
- Telefonnummer: 476510304
- E-Mail: i.vivodtzev@agiradom.com
Studienorte
-
-
-
Grenoble, Frankreich
- Rekrutierung
- Hopital Universitaire
-
Kontakt:
- Jean-Louis Pepin, MD, PhD
- Telefonnummer: 0476765516
- E-Mail: JPepin@chu-grenoble.fr
-
Kontakt:
- Isabelle, Vivodtzev, PhD
- Telefonnummer: 0476510304
- E-Mail: i.vivodtzev@agiradom.com
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Male or female, aged over 18 years
- Morbid obesity (BMI > 35 kg/m²)
- Not included into exercise training program in the year prior to inclusion- Spontaneous physical activity lower than 160 min wk (i.e. < 30 min/d x 5 d/wk).
Additional Inclusion criteria for the interventional study:
- Patients with PWV > 9.3 m / s
Exclusion Criteria:
- Underage- Pregnant or parturient women
- Persons deprived of their liberty for judicial or administrative reasons, person under a legal protection measure (article L1121-8)
- Exclusion period in other studies- Person not affiliated to a social security scheme
- Chronic alcoholism
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Crossover-Aufgabe
- Maskierung: Single
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Sonstiges: m-NMES first
Multisite electrostimulator first (Visit 1) and conventional electrostimulator then (Visit 2)
|
Andere Namen:
|
Sonstiges: c-NMES first
Conventional electrostimulator first (Visit 1) and multisite electrostimulator then (Visit 2)
|
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Delta arterial stiffness
Zeitfenster: Day1 and Day3
|
Change in carotid-femoral Pulse wave velocity (PWV) after NMES sessions
|
Day1 and Day3
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Delta pulse arterial tonus (RH-PAT)
Zeitfenster: Day1 and Day3
|
change in pulse arterial tonometry after NMES sessions
|
Day1 and Day3
|
NMES-induced muscle fatigue
Zeitfenster: Day1 and Day3
|
change in maximal voluntary contraction after NMES sessions
|
Day1 and Day3
|
Delta blood pressure
Zeitfenster: Day1 and Day3
|
changes in systolic and diastolic blood pressures after NMES sessions
|
Day1 and Day3
|
Delta plasmatic biomarkers
Zeitfenster: Day1 and Day3
|
changes in inflammatory and metabolic plasmatic biomarkers after NMES sessions
|
Day1 and Day3
|
Body composition
Zeitfenster: Day1, Day21 and Day 42
|
Fat-free mass and fat-free mass indexes assessed by impedancemetry
|
Day1, Day21 and Day 42
|
Spontaneous physical activity
Zeitfenster: Day1 and Day 42
|
Number of hours per day of physical activity at 1, 2, 3, 4 or 5 metabolic equivalent(METS),Number of step per day,using a 7-days actigraphy
|
Day1 and Day 42
|
Maximal voluntary contraction
Zeitfenster: Day1, Day21 and Day 42
|
Quadriceps peak force
|
Day1, Day21 and Day 42
|
Walking distance
Zeitfenster: Day1 and Day 42
|
6-minute-walking test
|
Day1 and Day 42
|
Arterial stiffness
Zeitfenster: Day1, Day21 and Day 42
|
Pulse wave velocity (PWV) measurements
|
Day1, Day21 and Day 42
|
Pulse artery tone (RH-PAT)
Zeitfenster: Day1, Day21 and Day 42
|
Pulse artery tonometry measurement
|
Day1, Day21 and Day 42
|
Plasmatic biomarkers
Zeitfenster: Day1, Day21 and Day 42
|
Inflammatory and metabolic biomarkers
|
Day1, Day21 and Day 42
|
Blood pressure
Zeitfenster: Day1, Day21 and Day 42
|
Arterial systolic and diastolic blood pressure
|
Day1, Day21 and Day 42
|
Response to m-NMES
Zeitfenster: Day42
|
Delta in current intensity during m-NMES between the first to the last session
|
Day42
|
Mitarbeiter und Ermittler
Sponsor
Mitarbeiter
Ermittler
- Hauptermittler: Jean-Louis Pépin, MD, PhD, Laboratoire EFCR, CHU de Grenoble, 38043, Grenoble, France
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Voraussichtlich)
Studienabschluss (Voraussichtlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Andere Studien-ID-Nummern
- 12-AGIR-04
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .